Home / Health / Epilepsy Drug Sparks 45% Stock Surge
Epilepsy Drug Sparks 45% Stock Surge
9 Mar
Summary
- Experimental epilepsy drug azetukalner met its primary trial goal.
- Patients on the drug showed significant reduction in monthly seizures.
- Analysts predict over $2 billion in peak sales for the drug.
Xenon Pharmaceuticals' experimental epilepsy drug, azetukalner, has demonstrated remarkable success in a late-stage trial, meeting its primary objective of significantly reducing focal onset seizures. Patients treated with azetukalner experienced a median reduction in monthly seizure frequency, with the 25 mg dose showing a 53.2% decrease and the 15 mg dose a 34.5% decrease over a 12-week period. The placebo-adjusted reduction for the higher dose was 42.7%, surpassing expectations.
These compelling results have generated considerable investor enthusiasm, with Xenon's shares climbing 45% following the announcement. Analysts are optimistic about azetukalner's market potential, with some projecting peak sales exceeding $2 billion. The drug's efficacy, particularly in treatment-resistant patient populations, is seen as a key differentiator from existing anti-seizure medications. Xenon plans to file for regulatory approval in the third quarter of 2026, anticipating a decision from the Food and Drug Administration by late 2027 or early 2028.
